Information from the abstract
BACKGROUND: All currently approved botulinum toxins for treatment of facial lines, such as glabellar lines (GL), are of serotype A (BoNT/A). OBJECTIVES: This 12-week, phase 3, double-blind (DB), placebo-controlled study evaluated the safety and efficacy for trenibotulinumtoxinE (trenibotE), a first-in-class botulinum toxin serotype E, in toxin-naïve adults with moderate to-severe GL. METHODS: Participants with no prior toxin treatment were randomized 3:1 to trenibotE (700 U) or placebo. The rigorous, multi-component primary endpoint was achieving grade 0 or 1 (None or Mild) with ≥ 2-grade improvement on the Facial Wrinkle Scale (FWS) at maximum frown at day 7, assessed by both investigator and participant. Additional endpoints included FWS improvements over time and patient-reported outcomes. Safety was monitored. RESULTS: Of 309 participants (79.3% female, 83.2% White, mean age of 43.1 years), the effects of trenibotE were observed at hour 8, peaked at day 7, and returned to moderate or severe severity by day 21. At day 7, 65.7% who received trenibotE achieved the primary endpoint vs 1.2% placebo (P < .0001). Treatment satisfaction at hour 24 and day 7 was higher in the trenibotE group (69.3% and 84.9%, respectively) than placebo (13.7% and 9.8%, respectively). At day 7, 84.7% of participants reported satisfaction with natural-looking results. Most TEAEs were mild, non-serious, and unrelated to treatment. There were no serious, treatment-related TEAEs and no cases consistent with distant spread of toxin. CONCLUSIONS: TrenibotE was well tolerated and improved GL severity in toxin-naïve participants, with rapid results and short duration of effect. Participants were satisfied with overall treatment and their natural-looking results.
Why this record is monitored
This record has an Impact Signal of 72/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.
Related topics: Botulinum Toxin and Related Neurological Disorders · Facial Rejuvenation and Surgery Techniques · Dermatologic Treatments and Research
Thai researcher and institutional participation
Rosalyn George · Institute of Dermatology
Data limitations
This page is a bibliographic record based on abstract-level information, not a full analysis or quality assessment. Verify the DOI and original article before citation.